This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Business Highlights

The ICO said in a statement that Google Inc. had agreed to delete all that data nearly two years ago, adding that its failure to do so "is cause for concern."

___

Chevron 2Q net income slips 7 percent

NEW YORK (AP) â¿¿ Soaring profit at Chevron's refineries eased some of the pain of a weaker second quarter.

The oil giant said Friday that net income fell nearly 7 percent to $7.21 billion, or $3.66 per share. But the results beat expectations thanks to a strong performance from its refinery business.

Like its peers, the oil giant is struggling to find and replace its sources of petroleum. The world's slowing economy has also pushed down prices for the crude it sells.

But the lower prices had benefits. Profits at Chevron's refining and marketing business rose 80 percent. Its refineries paid less for oil while selling gasoline at higher prices on the U.S. West Coast. Pump prices there remained well above the national average last quarter because of supply problems in the region. The business also sold about $200 million in assets, including its stake in a South Korean energy business.

___

Merck's 2Q net falls on charges, but sales rise

Shares of drugmaker Merck & Co. surged over 4 percent to a new high for the year Friday as its second-quarter results easily beat Wall Street expectations â¿¿ just as generic competition is set to start decimating sales of its top-selling medicine, Singulair.

The world's third-biggest drugmaker by revenue maintained its profit forecast despite net income dropping 11.4 percent as higher sales were offset by unfavorable currency rates and acquisition and restructuring costs. Still, adjusted profit was up 9 percent, and it was Merck's sixth straight quarter with revenue and adjusted income both up.

The maker of diabetes pill Januvia and asthma and allergy medicine Singulair said net income was $1.79 billion, or 58 cents per share. That was down from $2.02 billion, or 65 cents per share, a year earlier, when results were boosted by a one-time, $700 million tax settlement gain.

3 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,493.37 -69.93 -0.42%
S&P 500 1,925.15 -5.52 -0.29%
NASDAQ 4,352.6390 -17.1340 -0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs